HAYWARD, Calif., June 14 /PRNewswire-FirstCall/ -- Solta Medical,
Inc. (Nasdaq: SLTM), a global leader in the medical aesthetics
market, today announced that it has been included on the list of
preliminary additions to the Russell 3000® Index and the Russell
Global® Index posted by Russell Investments on June 11, 2010 on www.russell.com. These changes
are expected to go into effect after the close of trading on
Friday, June 25, 2010. All
Russell indexes are subindexes of the Global Index.
"Solta's preliminary addition to the Russell 3000 Index is a
positive step for our shareholders and will help increase awareness
of our Company," said Stephen J.
Fanning, Chairman of the Board, President and CEO.
"Inclusion in the Russell 3000 should allow us to expand our range
of potential institutional investors as we look to increase our
market presence domestically and abroad."
The Russell 3000 Index measures the performance of the 3,000
largest publicly-traded U.S. companies, representing approximately
98% of the U.S. equity market. The Russell indexes are widely used
by investment managers and institutional investors for index funds
and as benchmarks for passive and active investment strategies. The
indexes are reconstituted annually.
About Solta Medical, Inc.
Solta Medical, Inc. is a global leader in the medical aesthetics
market providing innovative, safe, and effective solutions for
patients that enhance and expand the practice of medical aesthetics
for physicians. The company offers products to address a range of
skin issues under the industry's three premier brands: Thermage(R),
Fraxel(R) and Isolaz(R). Thermage is an innovative, non-invasive
radiofrequency procedure for tightening and contouring skin. As the
leader in fractional laser technology, Fraxel delivers minimally
invasive clinical solutions to resurface aging and sun damaged
skin. Isolaz is the only laser or light based system indicated for
the treatment of inflammatory acne, comedonal acne, pustular acne,
and mild-to-moderate inflammatory acne. Since 2002, approximately
one million Thermage, Fraxel and Isolaz procedures have been
performed in over 100 countries. For more information about Solta
Medical, call 1-877-782-2286 or log on to www.Solta.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995. Forward-looking statements are based on management's current,
preliminary expectations and are subject to risks and
uncertainties, which may cause Solta Medical's actual results to
differ materially from the statements contained herein. Further
information on potential risk factors that could affect Solta
Medical's business and its financial results are detailed in its
Form 10-K for the year ended December 31,
2009, and other reports as filed from time to time with the
Securities and Exchange Commission. Undue reliance should not be
placed on forward-looking statements which speak only as of the
date they are made. Solta Medical undertakes no obligation to
update publicly any forward-looking statements to reflect new
information, events or circumstances after the date they were made,
or to reflect the occurrence of unanticipated events.
SOURCE Solta Medical, Inc.